The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

Diabetes remission was achieved in 44 and 28% of patients in the dapagliflozin and placebo groups, respectively. HealthDay News — For patients with overweight or obesity and type 2 diabetes ...

After adjusting for potential confounders (age, sex, race, use of birth control, pregnancy), findings showed propranolol use was associated with a significant reduction in the risk of stroke among ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...